CureVac (NASDAQ:CVAC) Shares Gap Up to $2.44

CureVac (NASDAQ:CVAC) gapped up before the market opened on Monday . The stock had previously closed at $2.44, but opened at $2.51. CureVac shares last traded at $2.49, with a volume of 88,287 shares traded.

Analyst Upgrades and Downgrades

Separately, Guggenheim reiterated a “neutral” rating on shares of CureVac in a research report on Friday, April 5th.

CureVac Stock Performance

The company has a quick ratio of 3.41, a current ratio of 3.56 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $3.12 and a two-hundred day moving average of $4.20.

Institutional Investors Weigh In On CureVac

Institutional investors and hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of CureVac by 95.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock worth $39,000 after acquiring an additional 2,804 shares during the period. Swiss National Bank grew its holdings in shares of CureVac by 1.8% in the 3rd quarter. Swiss National Bank now owns 221,406 shares of the company’s stock worth $1,462,000 after acquiring an additional 3,925 shares during the period. Pathstone Family Office LLC acquired a new stake in shares of CureVac in the 3rd quarter worth approximately $89,000. Deutsche Bank AG grew its holdings in shares of CureVac by 5.1% in the 3rd quarter. Deutsche Bank AG now owns 72,510 shares of the company’s stock worth $495,000 after acquiring an additional 3,491 shares during the period. Finally, Federated Hermes Inc. grew its holdings in shares of CureVac by 33.3% in the 3rd quarter. Federated Hermes Inc. now owns 40,000 shares of the company’s stock worth $273,000 after acquiring an additional 10,000 shares during the period. Institutional investors and hedge funds own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.